News
7h
Zacks Investment Research on MSNPTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue EstimatesPTC Therapeutics (PTCT) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.16 per share a year ago. These figures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results